Cargando…
Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia
Pediatric leukemia survival rates have improved dramatically over the past decades. However, current treatment protocols are still largely ineffective in cases of relapsed leukemia and are associated with a significant rate of chronic health conditions. Thus, there is a continued need for new therap...
Autores principales: | Brandao, L N, Winges, A, Christoph, S, Sather, S, Migdall-Wilson, J, Schlegel, J, McGranahan, A, Gao, D, Liang, X, DeRyckere, D, Graham, D K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3556576/ https://www.ncbi.nlm.nih.gov/pubmed/23353780 http://dx.doi.org/10.1038/bcj.2012.46 |
Ejemplares similares
-
MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines
por: Kim, Jung Eun, et al.
Publicado: (2017) -
Prolonged Exposure to a Mer Ligand in Leukemia: Gas6 Favors Expression of a Partial Mer Glycoform and Reveals a Novel Role for Mer in the Nucleus
por: Migdall-Wilson, Justine, et al.
Publicado: (2012) -
Harnessing MerTK agonism for targeted therapeutics
por: Kedage, Vivekananda, et al.
Publicado: (2019) -
MerTK, a risk factor for NASH fibrosis
por: Wang, Xiaobo, et al.
Publicado: (2020) -
Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer
por: Cummings, Christopher T., et al.
Publicado: (2014)